

**Trademark Snap Shot ITU Unit Action**  
(Table presents the data on ITU Unit Action)

**OVERVIEW**

SERIAL NUMBER	77309541	FILING DATE	10/22/2007
REG NUMBER	0000000	REG DATE	N/A
REGISTER	PRINCIPAL	MARK TYPE	TRADEMARK
INTL REG #	N/A	INTL REG DATE	N/A
TM ATTORNEY	BESCH, JAY C	L.O. ASSIGNED	108

**PUB INFORMATION**

RUN DATE	08/03/2010
PUB DATE	10/07/2008
STATUS	606-ABANDONED - NO STATEMENT OF USE FILED
STATUS DATE	08/02/2010
LITERAL MARK ELEMENT	STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS

DATE ABANDONED	08/02/2010	DATE CANCELLED	N/A
SECTION 2F	NO	SECTION 2F IN PART	NO
SECTION 8	NO	SECTION 8 IN PART	NO
SECTION 15	NO	REPUB 12C	N/A
RENEWAL FILED	NO	RENEWAL DATE	N/A
DATE AMEND REG	N/A		

**FILING BASIS**

FILED BASIS		CURRENT BASIS		AMENDED BASIS	
1 (a)	NO	1 (a)	NO	1 (a)	NO
1 (b)	YES	1 (b)	YES	1 (b)	NO
44D	NO	44D	NO	44D	NO
44E	NO	44E	NO	44E	NO
66A	NO	66A	NO		
NO BASIS	NO	NO BASIS	NO		

**MARK DATA**

STANDARD CHARACTER MARK	YES
LITERAL MARK ELEMENT	STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS
MARK DRAWING CODE	4-STANDARD CHARACTER MARK
COLOR DRAWING FLAG	NO

**CURRENT OWNER INFORMATION**

PARTY TYPE	20-OWNER AT PUBLICATION
NAME	Glaxo Group Limited
ADDRESS	Glaxo Wellcome House, Berkeley Avenue Greenford, Middlesex, UK

ENTITY	03-CORPORATION
CITIZENSHIP	GB2
<b>GOODS AND SERVICES</b>	
INTERNATIONAL CLASS	016
DESCRIPTION TEXT	Printed materials, namely, pamphlets and brochures featuring the treatment and prevention of cardiovascular diseases and disorders
INTERNATIONAL CLASS	042
DESCRIPTION TEXT	Medical and scientific research, namely, conducting clinical trials for pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders

<b>GOODS AND SERVICES CLASSIFICATION</b>							
INTERNATIONAL CLASS	016	FIRST USE DATE	NONE	FIRST USE IN COMMERCE DATE	NONE	CLASS STATUS	6-ACTIVE
INTERNATIONAL CLASS	042	FIRST USE DATE	NONE	FIRST USE IN COMMERCE DATE	NONE	CLASS STATUS	6-ACTIVE

<b>MISCELLANEOUS INFORMATION/STATEMENTS</b>	
CHANGE IN REGISTRATION	NO
DISCLAIMER W/PREDETER TXT	"SELECTIVE TREATMENT OF ATHEROSCLEROSIS:DARAPLADIB INHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS"
PSEUDO MARK	STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INHIBITS LP-PLA TWO WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS

<b>PROSECUTION HISTORY</b>				
DATE	ENT CD	ENT TYPE	DESCRIPTION	ENT NUM
08/02/2010	MAB6	O	ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED	037
08/02/2010	ABN6	S	ABANDONMENT - NO USE STATEMENT FILED	036
05/12/2010	TCCA	I	TEAS CHANGE OF CORRESPONDENCE RECEIVED	035
05/03/2010	TCCA	I	TEAS CHANGE OF CORRESPONDENCE RECEIVED	034
01/30/2010	EX2G	S	EXTENSION 2 GRANTED	033
12/21/2009	EXT2	S	EXTENSION 2 FILED	032
01/29/2010	AITU	A	CASE ASSIGNED TO INTENT TO USE PARALEGAL	031
12/21/2009	EEXT	I	TEAS EXTENSION RECEIVED	030
10/29/2009	TCCA	I	TEAS CHANGE OF CORRESPONDENCE RECEIVED	029
07/22/2009	EX1G	S	EXTENSION 1 GRANTED	028
06/29/2009	EXT1	S	EXTENSION 1 FILED	027
07/22/2009	AITU	A	CASE ASSIGNED TO INTENT TO USE PARALEGAL	026
06/29/2009	EEXT	I	TEAS EXTENSION RECEIVED	025
06/02/2009	ARAA	I	ATTORNEY REVOKED AND/OR APPOINTED	024
06/02/2009	REAP	I	TEAS REVOKE/APPOINT ATTORNEY RECEIVED	023
12/30/2008	NOAM	O	NOA MAILED - SOU REQUIRED FROM APPLICANT	022
10/07/2008	PUBO	A	PUBLISHED FOR OPPOSITION	021

09/04/2008	PREV	O	LAW OFFICE PUBLICATION REVIEW COMPLETED	019
09/04/2008	ALIE	A	ASSIGNED TO LIE	018
08/26/2008	CNSA	P	APPROVED FOR PUB - PRINCIPAL REGISTER	017
08/26/2008	XAEC	I	EXAMINER'S AMENDMENT ENTERED	016
08/26/2008	GNEN	O	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED	015
08/26/2008	GNEA	O	EXAMINERS AMENDMENT E-MAILED	014
08/26/2008	CNEA	R	EXAMINERS AMENDMENT -WRITTEN	013
06/26/2008	GNFN	O	NOTIFICATION OF FINAL REFUSAL EMAILED	012
06/26/2008	GNFR	O	FINAL REFUSAL E-MAILED	011
06/26/2008	CNFR	R	FINAL REFUSAL WRITTEN	010
06/06/2008	TEME	I	TEAS/EMAIL CORRESPONDENCE ENTERED	009
06/06/2008	CRFA	I	CORRESPONDENCE RECEIVED IN LAW OFFICE	008
06/06/2008	TROA	I	TEAS RESPONSE TO OFFICE ACTION RECEIVED	007
12/07/2007	GNRN	O	NOTIFICATION OF NON-FINAL ACTION E-MAILED	006
12/07/2007	GNRT	F	NON-FINAL ACTION E-MAILED	005
12/07/2007	CNRT	R	NON-FINAL ACTION WRITTEN	004
12/03/2007	DOCK	D	ASSIGNED TO EXAMINER	003
10/26/2007	MPMK	O	NOTICE OF PSEUDO MARK MAILED	002
10/25/2007	NWAP	I	NEW APPLICATION ENTERED IN TRAM	001

#### CURRENT CORRESPONDENCE INFORMATION

ATTORNEY	Christopher M. Hanes
CORRESPONDENCE ADDRESS	Christopher M. Hanes GlaxoSmithKline Five Moore Drive LGTM, C.3157.3D Research Triangle Park NC 27709
DOMESTIC REPRESENTATIVE	Christopher M. Hanes

#### PRIOR OWNER INFORMATION

PARTY TYPE	10-ORIGINAL APPLICANT
NAME	Glaxo Group Limited
ADDRESS	Glaxo Wellcome House, Berkeley Avenue Greenford, Middlesex, UB60NN
ENTITY	03-CORPORATION
CITIZENSHIP	GB2

STABILISE SELECTIVE  
TREATMENT OF  
ATHEROSCLEROSIS:  
DARAPLADIB INHIBITS  
LP-PLA2 WITH  
ANTI-INFLAMMATORY AND  
PLAQUE STABILISING EFFECTS